Caprion is proud to offer an expanded range of solutions for clinical and translational research

with the addition of IMMUNECARTA Services to complement its established proteomic biomarker

services business. The pairing of Caprion’s traditional strengths in biomarker and target discovery

with IMMUNECARTA’s immune monitoring expertise, provides a powerful combination of solutions

for all phases of drug and vaccine development.

IMMUNECARTA’s capabilities include analysis of phenotypic and functional profiles of innate and adaptive immune responses in

a GLP/GCLP compliant environment. Our immune monitoring expertise is applied to preclinical drug development and phase I/II

clinical trials across many key therapeutic indications.

ThERApEUTIC AREAS

IMMUNE MONITORING SERVICES

gCellular therapy

gDrug therapy

gCancer immunotherapy

gVaccine development

gInfectious diseases

gAutoimmune disorders

gChronic inflammatory diseases

gImmunosenescence

gFlow cytometry-based assays

gMultiplex beads-based assays

gELISpot assays

gELISA assays

ASSAY TYpESThe IMMUNECARTA team has enabled a number of different assay formats for

assessment of subtle and often complex changes in immune response. Each assay may be customized to address

client and study-specific needs for flexibility and scalability for vaccine trials, immunotherapy trials, or part of an overall

assessment of immunocompetence or immune reconstitution as a result of therapy.

For a comprehensive overview of assays, see chart inside.

CA

P_2

01_2

012

Integrated solutions for the advancement of personalized medicine

For more information contact us at 1-877-776-3443 or info@caprion.com

ExpERIENCE ThE dIffERENCE

caprion.comIN IMMUNE MONITORING

plaTfORM fIEld Of applICaTION MaIN ThERapEUTIC aREa

CaTEGORIES Of aSSaySBIOlOGICal

COMpaRTMENTMaRkERS

CU

ST

OM

Iza

Bl

E

flO

w C

yT

OM

ET

Ry

Cy

TO

kIN

E B

Ea

d

aR

Ra

y (

CB

a)

El

ISa

/El

ISp

OT

Ch

EM

IlU

MIN

ES

CE

NC

E

MO

lE

CU

la

R

BIO

lO

Gy

dR

UG

dE

VE

lO

pM

EN

T

BIO

Ma

Rk

ER

S

BIO

lO

GIC

S/

BIO

SIM

Ila

RS

IMM

UN

E

MO

NIT

OR

ING

Va

CC

INE

Ep

ITO

pE

M

ap

pIN

G

IMM

UN

OTO

xIC

OlO

Gy

INf

EC

TIO

US

d

ISE

aS

ES

al

lE

RG

y

ON

CO

lO

Gy

Ca

Rd

IOlO

Gy

aU

TO

IMM

UN

ITy

TR

aN

Sp

la

NTa

TIO

N

IMM

UN

E

SE

NE

SC

EN

CE

Ch

RO

NIC

IN

fl

aM

Ma

TIO

N

Cellular enumeration

hematopoietic stem cells Circulating Cd34+ Cd34, Cd45, others 4 • • • • • •

Immune Cells T, B and Innate cellsCd3, Cd4, Cd8, Cd16/56, Cd19, Cd14, Cd11c, Cd45,

Cd123, others4 • • • • • • • • • • • • • •

Cellular PhenotyPing

Cell lineage

T cells

B cells

Nk cells

NkT cells

dendritic cells

Basophils

Monocytes

Cd3, Cd4, Cd8

Cd19, hla-dR

Cd16, Cd56, lin-

Va24, aGalCerCd1d tetramer, Cd3

Cd11c, Cd123, lin-

Cd123, lin-

Cd14

4 • • • • • • • • • • • • • • •

Cell Subset differentiation

T cells

B cells

Nk cells

dendritic cells

Basophils

Monocytes

Cd45Ra/RO, Cd27, CCR7, Cd28, Cd62l

Cd27, Igd/M, Cd20, Cd38, Cd10, Iga/G/E

Cd94/NkG2a, Cd7, kIR2dl/dS

Cd11c, Cd123, BdCa-2/3/4,

fcgRs, IgE, CCR3

Cd16, Cd64, fcgRs

4 • • • • • • • • • • • • • • •

antigenic specificity antigen-specific Cd8+/Cd4+ T cellsantigen-specific, hla-restricted TCR

(using Tetramer/pentamer/dexamer)4 • • • • • • • • • •

activation/Inhibition/

Exhaustion/Immune

Senescence

T, B and Innate cells

hla-dR, Cd38, ICOS, Ox40, 4-1BB, ki67, Cd40,

Cd95, pd-1, Cd57, Cd83, Cd80, Cd86, Cd160,

lag-3, 2B4, CTla-4, Tim-34 • • • • • • • • • • • • • • •

homing Receptors/

Co-receptorsT cells, B and Innate cells

CCR4, CCR5, CCR6, CCR7, CCR9, CxCR3,

a4b7 integrins, others4 • • • • • • • • • • • • •

Transcriptional factors Treg, Th1, Th2, Th17, Tfh foxp3, T-bet, GaTa-3, RORgt, BCl-6 4 • • • • • • • • • • •

FunCtional ProFiling

Intracellular Cytokine/

Chemokine Staining (ICS)

T, B, Nk, NkT, dendritic cells,

Monocytes

Il-2, TNfa, IfNg, Il-4, Il-17, Il-22, Il-10, TGfb,

Il-9, Il-21, Mip1b, others4 • • • • • • • • • • • • • • •

apoptosis/Necrosis T, B and Innate cellsannexin, caspase 3, Cd95, paRp, TUNEl,

live/dead, 7-aad4 • • • • • • • • • • • • • • •

phosphorylation

(phosflow)

T, B and Innate Cells,

Tumor cells

akt, Btk, Elk, EGf-R, lck, laT, zap70, Syk,

MEk1, NfkB, pkC, plC-g1, plC-g2, p38Mapk,

ERkk1/2 Src, STaT1 to STaT-64 • • • • • • • • • • • • •

proliferative capacity

(Immuknow®)Total Cd4 cells aTp • • • • • • • • • •

proliferative response/

cell cyclingT cells and subsets CfSE, ki67, BrdU 4 • • • • • • • • • • • • • • • •

ElISpOT Cd8+/Cd4+ T cells, B cells IfNg and/or Il-2, TNfa, IgG, IgM 4 • • • • • • • • •

Cytotoxicity/degranulationT, Nk, NkT cells and

subsets, BasophilsCd107a, Granzyme, perforin, Cd63, others 4 • • • • • • • • • • • • • • •

Serology & Soluble markerS

antibody TitersSerum, plasma, cell culture superna-

tants

Tetanus, diphtheria, hepatitis B, Cholera toxin B,

CMV, others • • • • • • • • • • •

Cytokines/Chemokines/

adhesion Molecules/Growth factors

Serum, plasma,cell culture superna-

tants

Interleukins, sICaM-1, sICaM-3, sVCaM-1,

spECaM-1, sE-Selectin, sp-Selectin, G-CSf, Il-8,

MCp-1, MIG, MIp-1a, MIp-1b, others4 • • • • • • • • • • • • • • • •

gene exPreSSion & Dna analySiS

mRNa expression

(real-time pCR)Cells, tissue Specific mRNa quantification 4 • • • • • • • • • • • • •

T cell receptor excision circles (TREC) Cells, tissue sjTREC • • • • • • • •

IMMUNECaRTa SERVICES: dEEp ExpERTISE IN IMMUNE RESpONSE MONITORING USING flOw CyTOMETRyIMMUNECaRTa aSSay MaTRIx

I M M U N E C A R T A C A P R I O N I M M U N E M O N I T O R I N G S O L U T I O N S

I M M U N E C A R T A C A P R I O N I M M U N E M O N I T O R I N G S O L U T I O N S

gFlow Cytometry – State-of-the art instrumentation with up to 14 colour multi-parametric technology

gImmune Cell Characterization – Discrimination and enumeration of immune cells and subtypes

according to phenotype, function and frequency

gBroad Assay Portfolio and Expertise – Cell-mediated immunity and epitope mapping.

Signaling pathways. Serology and profiling of soluble markers

gValidated Assays – Off-the-shelf kits or on-demand fully customized and validated assays

gLogistics Support – Coordination of sample procurement and analysis, client training

gSample Collection and Processing Services – Validated protocols with option to direct-ship samples

from clinical sites for centralized processing by IMMUNECARTA Services.

gOnsite or Web-Based Training Options – For multi-center trials and remote clinical sites to ensure

consistent sample processing and preparation across sites

IMMUNE MONITORING CApABILITIES

Integrated solutions for the advancement of personalized medicine

CONSULTING SERVICESgImmunology and Technical Expertise – For assessment of study requirements appropriate to the

immune responses of interest. Scientific intellectual leadership and study management of active programs

gTrial Design – As per client need, for delineation of subtle immunologic events and clinical endpoint measurement

gAssay Selection – Evaluation and recommendations for development, customization, validation and deployment

gData Interpretation – Synthesis, analysis and interpretation of complex datasets to infer biological significance

and convey meaning to the immune response, by expert staff immunologists

QUALITY MANAGEMENT SYSTEMgGood Laboratory Practice – IMMUNECARTA operates in accordance with applicable GLP/GCLP regulations

and guidelines, under which studies are planned, conducted, monitored, reported and archived

gQuality Management System – Ensures validation and standardization of immune assays with

rigorous quality control standards, from sample collection to final data reporting

gSuccessful Quality Audits – Successfully audited by a number of major

pharmaceutical clients and independent auditing firms

For more information contact us at 1-877-776-3443 or info@caprion.com

1

2

3